Additionnally, HULC has also been shown to promote the progression of other systemic cancers, including breast cancer, lung cancer, ovarian cancer, and osteosarcoma (16–19).For instance, HULC promotes the metastasis and cisplatin resistance of triple-negative breast cancer cells by targeting the trans-IGF1R-PI3K-AKT axis35981570. Here, HULC is linked to osteosarcoma.